Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Randomized Open-label Study of Oseltamivir Combined With HD-DEX Versus HD-DEX in the Management of ITP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* newly diagnosed ITP patients need of treatment(s) to minimize the risk of clinically significant bleeding primary ITP confirmed by excluding other supervened causes of thrombocytopenia~Exclusion Criteria:~* pregnancy hypertension cardiovascular disease diabetes liver and kidney function impairment HCV, HIV, HBsAg seropositive status patients with systemic lupus erythematosus and/or antiphospholipid syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Oseltamivir Combining HD-DXM (Type: ACTIVE_COMPARATOR): Oseltamivir 75 mg twice per day, 10consecutive days~HD-DXM (orally at 40 mg daily for 4d )
- HD-DXM (Type: ACTIVE_COMPARATOR): HD-DXM (orally at 40 mg daily for 4d )

Based on this trial design, predict the completion outcome and termination type (if applicable).